Cracking the ANP32 whips: Important functions, unequal requirement, and hints at disease implications

BioEssays

Volumn 36, Issue 11, 2014, Pages 1062-1071

  Reilly, Patrick T ^a   Yu, Yun ^b   Hamiche, Ali ^c   Wang, Lishun ^b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Caspase regulation; Chromatin regulation; Intracellular transport; Leucine rich repeats; Low complexity acidic region; Phosphatase inhibition

Indexed keywords

ACIDIC LEUCINE RICH NUCLEAR PHOSPHOPROTEIN 32A; ACIDIC LEUCINE RICH NUCLEAR PHOSPHOPROTEIN 32B; ACIDIC LEUCINE RICH NUCLEAR PHOSPHOPROTEIN 32E; APOPTOSOME; CASPASE; CASPASE 3; CHAPERONE; HISTONE; HISTONE H3; MESSENGER RNA; PHOSPHOPROTEIN; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2A; UNCLASSIFIED DRUG; ANP32A PROTEIN, HUMAN; ANP32B PROTEIN, HUMAN; ANP32C PROTEIN, HUMAN; ANP32E PROTEIN, HUMAN; CHROMATIN; NUCLEAR PROTEIN; SIGNAL PEPTIDE;

ALZHEIMER DISEASE; ARTICLE; CANCER GROWTH; CARCINOGENICITY; CELL DEATH; CHROMATIN STRUCTURE; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HUMAN; INTRACELLULAR TRANSPORT; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOSOME; PATHOGENESIS; PHENOTYPE; POSITIVE FEEDBACK; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; STRUCTURAL HOMOLOGY; TRANSCRIPTION REGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; GENETICS; METABOLISM; NEOPLASM; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; PROTEIN TRANSPORT;

ANIMALS; APOPTOSIS; CASPASES; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; NUCLEAR PROTEINS; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT;

EID: 84907879203     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201400058     Document Type: Article

References (118)

1. Vaesen M, Barnikol-Watanabe S, Gotz H, Awni LA, et al. 1994. Purification and characterization of two putative HLA class II associated proteins: PHAPI and PHAPII. Biol Chem Hoppe Seyler 375: 113-26.
2. Matilla A, Radrizzani M. 2005. The Anp32 family of proteins containing leucine-rich repeats. Cerebellum 4: 7-18.
3. Kobe B, Kajava AV. 2001. The leucine-rich repeat as a protein recognition motif. Curr Opin Struct Biol 11: 725-32.
4. de Chiara C, Kelly G, Frenkiel TA, Pastore A. 2007. NMR assignment of the leucine-rich repeat domain of LANP/Anp32a. J Biomol NMR 38: 177.
5. Huyton T, Wolberger C. 2007. The crystal structure of the tumor suppressor protein pp32 (Anp32a): structural insights into Anp32 family of proteins. Protein Sci 16: 1308-15.
6. Tochio N, Umehara T, Munemasa Y, Suzuki T, et al. 2010. Solution structure of histone chaperone ANP32B: interaction with core histones H3-H4 through its acidic concave domain. J Mol Biol 401: 97-114.
7. Brennan CM, Gallouzi IE, Steitz JA. 2000. Protein ligands to HuR modulate its interaction with target mRNAs in vivo. J Cell Biol 151: 1-14.
8. Chen S, Li B, Grundke-Iqbal I, Iqbal K. 2008. I1PP2A affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A. J Biol Chem 283: 10513-21.
9. Matilla A, Koshy BT, Cummings CJ, Isobe T, et al. 1997. The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1. Nature 389: 974-8.
10. Kuehl L, Childers TJ, McCauley RM. 1986. The occurrence of extended acidic sequences in nonhistone chromosomal proteins. Arch Biochem Biophys 248: 272-81.
11. Earnshaw WC. 1987. Anionic regions in nuclear proteins. J Cell Biol 105: 1479-82.
12. Ye J, McGinnis S, Madden TL. 2006. BLAST: improvements for better sequence analysis. Nucleic Acids Res 34: W6-9.
13. Matsuoka K, Taoka M, Satozawa N, Nakayama H, et al. 1994. A nuclear factor containing the leucine-rich repeats expressed in murine cerebellar neurons. Proc Natl Acad Sci USA 91: 9670-4.
14. Hong R, Macfarlan T, Kutney SN, Seo SB, et al. 2004. The identification of phosphorylation sites of pp32 and biochemical purification of a cellular pp32-kinase. Biochemistry 43: 10157-65.
15. Fries B, Heukeshoven J, Hauber I, Gruttner C, et al. 2007. Analysis of nucleocytoplasmic trafficking of the HuR ligand APRIL and its influence on CD83 expression. J Biol Chem 282: 4504-15.
16. Ulitzur N, Rancano C, Pfeffer SR. 1997. Biochemical characterization of mapmodulin, a protein that binds microtubule-associated proteins. J Biol Chem 272: 30577-82.
17. Pan W, da Graca LS, Shao Y, Yin Q, et al. 2009. PHAPI/pp32 suppresses tumorigenesis by stimulating apoptosis. J Biol Chem 284: 6946-54.
18. Kendall RT, Strungs EG, Rachidi SM, Lee MH, et al. 2011. The beta-arrestin pathway-selective type 1A angiotensin receptor (AT1A) agonist [Sar1, Ile4, Ile8]angiotensin II regulates a robust G protein-independent signaling network. J Biol Chem 286: 19880-91.
19. Li M, Guo H, Damuni Z. 1995. Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney. Biochemistry 34: 1988-96.
20. Fan Z, Beresford PJ, Oh DY, Zhang D, et al. 2003. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell 112: 659-72.
21. Seo SB, McNamara P, Heo S, Turner A, et al. 2001. Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell 104: 119-30.
22. Switzer CH, Cheng RY, Vitek TM, Christensen DJ, et al. 2011. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 30: 2504-13.
23. Christensen DJ, Ohkubo N, Oddo J, Van Kanegan MJ, et al. 2011. Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol 186: 2535-42.
24. Christensen DJ, Chen Y, Oddo J, Matta KM, et al. 2011. SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. Blood 118: 4150-8.
25. Agarwal A, MacKenzie RJ, Pippa R, Eide CA, et al. 2014. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res 20: 2092-103.
26. Fujiwara N, Kawasaki H, Yabe R, Christensen DJ, et al. 2013. A potential therapeutic application of SET/I2PP2A inhibitor OP449 for canine T-cell lymphoma. J Vet Med Sci 75: 349-54.
27. Jiang X, Kim HE, Shu H, Zhao Y, et al. 2003. Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science 299: 223-6.
28. Malek SN, Katumuluwa AI, Pasternack GR. 1990. Identification and preliminary characterization of two related proliferation-associated nuclear phosphoproteins. J Biol Chem 265: 13400-9.
29. Obri A, Ouararhni K, Papin C, Diebold ML, et al. 2014. ANP32E is a histone chaperone that removes H2A.Z. from chromatin. Nature 505: 648-53.
30. Buddaseth S, Gottmann W, Blasczyk R, Huyton T. 2013. Overexpression of the pp32r1 (ANP32C) oncogene or its functional mutant pp32r1Y140H confers enhanced resistance to FTY720 (Finguimod). Cancer Biol Ther 15: 289-96.
31. Buddaseth S, Gottmann W, Blasczyk R, Huyton T. 2013. Dysregulation of cell cycle control caused by overexpression of the oncogene pp32r1 (ANP32C) and the Tyr>His mutant pp32r1Y140H. Biochim Biophys Acta 1833: 1212-21.
32. Imamachi K, Higashino F, Kitamura T, Kakuguchi W, et al. 2014. pp32r1 controls the decay of the RNA-binding protein HuR. Oncol Rep 31: 1103-8.
33. Kadkol SS, Brody JR, Pevsner J, Bai J, et al. 1999. Modulation of oncogenic potential by alternative gene use in human prostate cancer. Nat Med 5: 275-9.
34. Kadkol SS, El Naga GA, Brody JR, Bai J, et al. 2001. Expression of pp32 gene family members in breast cancer. Breast Cancer Res Treat 68: 65-73.
35. Kochevar GJ, Brody JR, Kadkol SS, Murphy KM, et al. 2004. Identification of a functional mutation in pp32r1 (ANP32C). Hum Mutat 23: 546-51.
36. Desiere F, Deutsch EW, King NL, Nesvizhskii AI, et al. 2006. The PeptideAtlas project. Nucleic Acids Res 34: D655-8.
37. Kadkol SS, Brody JR, Epstein JI, Kuhajda FP, et al. 1998. Novel nuclear phosphoprotein pp32 is highly expressed in intermediate- and high-grade prostate cancer. Prostate 34: 231-7.
38. Khan MZ, Vaidya A, Meucci O. 2011. CXCL12-mediated regulation of ANP32A/Lanp, a component of the inhibitor of histone acetyl transferase (INHAT) complex, in cortical neurons. J Neuroimmune Pharmacol 6: 163-70.
39. Mutai H, Toyoshima Y, Sun W, Hattori N, et al. 2000. PAL31, a novel nuclear protein, expressed in the developing brain. Biochem Biophys Res Commun 274: 427-33.
40. Hostetter C, Licata LA, Witkiewicz A, Costantino CL, et al. 2008. Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol Ther 7: 1496-506.
41. Zhu BD, Li XL, Liu Y, Chang J, et al. 2010. Involvement of hepatopoietin Cn in the development of human hepatocellular carcinoma. Clin Exp Metastasis 27: 571-80.
42. Martinvalet D, Zhu P, Lieberman J. 2005. Granzyme A induces caspase-independent mitochondrial damage, a required first step for apoptosis. Immunity 22: 355-70.
43. Tsujio I, Zaidi T, Xu J, Kotula L, et al. 2005. Inhibitors of protein phosphatase-2A from human brain structures, immunocytological localization and activities towards dephosphorylation of the Alzheimer type hyperphosphorylated tau. FEBS Lett 579: 363-72.
44. Ulitzur N, Humbert M, Pfeffer SR. 1997. Mapmodulin: a possible modulator of the interaction of microtubule-associated proteins with microtubules. Proc Natl Acad Sci USA 94: 5084-9.
45. Callebaut C, Blanco J, Benkirane N, Krust B, et al. 1998. Identification of V3 loop-binding proteins as potential receptors implicated in the binding of HIV particles to CD4(+) cells. J Biol Chem 273: 21988-97.
46. Chang J, Liu Y, Zhang DD, Zhang DJ, et al. 2010. Hepatopoietin Cn suppresses apoptosis of human hepatocellular carcinoma cells by up-regulating myeloid cell leukemia-1. World J Gastroenterol 16: 193-200.
47. Opal P, Garcia JJ, Propst F, Matilla A, et al. 2003. Mapmodulin/leucine-rich acidic nuclear protein binds the light chain of microtubule-associated protein 1B and modulates neuritogenesis. J Biol Chem 278: 34691-9.
48. Kovacech B, Kontsekova E, Zilka N, Novak P, et al. 2007. A novel monoclonal antibody DC63 reveals that inhibitor 1 of protein phosphatase 2A is preferentially nuclearly localised in human brain. FEBS Lett 581: 617-22.
49. Schneider R, Bannister AJ, Weise C, Kouzarides T. 2004. Direct binding of INHAT to H3 tails disrupted by modifications. J Biol Chem 279: 23859-62.
50. Seo SB, Macfarlan T, McNamara P, Hong R, et al. 2002. Regulation of histone acetylation and transcription by nuclear protein pp32, a subunit of the INHAT complex. J Biol Chem 277: 14005-10.
51. Cvetanovic M, Rooney RJ, Garcia JJ, Toporovskaya N, et al. 2007. The role of LANP and ataxin 1 in E4F-mediated transcriptional repression. EMBO Rep 8: 671-7.
52. Hunter CS, Malik RE, Witzmann FA, Rhodes SJ. 2013. LHX3 interacts with inhibitor of histone acetyltransferase complex subunits LANP and TAF-1beta to modulate pituitary gene regulation. PLoS One 8: e68898.
53. Kadota S, Nagata K. 2011. pp32, an INHAT component, is a transcription machinery recruiter for maximal induction of IFN-stimulated genes. J Cell Sci 124: 892-9.
54. Loven MA, Davis RE, Curtis CD, Muster N, et al. 2004. A novel estrogen receptor alpha-associated protein alters receptor-deoxyribonucleic acid interactions and represses receptor-mediated transcription. Mol Endocrinol 18: 2649-59.
55. Munemasa Y, Suzuki T, Aizawa K, Miyamoto S, et al. 2008. Promoter region-specific histone incorporation by the novel histone chaperone ANP32B and DNA-binding factor KLF5. Mol Cell Biol 28: 1171-81.
56. Mao Z, Pan L, Wang W, Sun J, et al. 2014. Anp32e, a higher eukaryotic histone chaperone directs preferential recognition for H2A.Z. Cell Res 24: 389-99.
57. Bargaje R, Alam MP, Patowary A, Sarkar M, et al. 2012. Proximity of H2A.Z. containing nucleosome to the transcription start site influences gene expression levels in the mammalian liver and brain. Nucleic Acids Res 40: 8965-78.
58. Nekrasov M, Amrichova J, Parker BJ, Soboleva TA, et al. 2012. Histone H2A.Z. inheritance during the cell cycle and its impact on promoter organization and dynamics. Nat Struct Mol Biol 19: 1076-83.
59. Coleman-Derr D, Zilberman D. 2012. Deposition of histone variant H2A.Z. within gene bodies regulates responsive genes. PLoS Genet 8: e1002988.
60. Guruharsha KG, Obar RA, Mintseris J, Aishwarya K, et al. 2012. Drosophila protein interaction map (DPiM): a paradigm for metazoan protein complex interactions. Fly 6: 246-53.
61. Gamble MJ, Erdjument-Bromage H, Tempst P, Freedman LP, et al. 2005. The histone chaperone TAF-I/SET/INHAT is required for transcription in vitro of chromatin templates. Mol Cell Biol 25: 797-807.
62. Kim HE, Jiang X, Du F, Wang X. 2008. PHAPI, CAS, and Hsp70 promote apoptosome formation by preventing Apaf-1 aggregation and enhancing nucleotide exchange on Apaf-1. Mol Cell 30: 239-47.
63. Hill MM, Adrain C, Duriez PJ, Creagh EM, et al. 2004. Analysis of the composition, assembly kinetics and activity of native Apaf-1 apoptosomes. EMBO J 23: 2134-45.
64. Fan Z, Zhang H, Zhang Q. 2006. Tumor suppressor pp32 represses cell growth through inhibition of transcription by blocking acetylation and phosphorylation of histone H3 and initiating its proapoptotic activity. Cell Death Differ 13: 1485-94.
65. Hoffarth S, Zitzer A, Wiewrodt R, Hahnel PS, et al. 2008. pp32/PHAPI determines the apoptosis response of non-small-cell lung cancer. Cell Death Differ 15: 161-70.
66. Schafer ZT, Parrish AB, Wright KM, Margolis SS, et al. 2006. Enhanced sensitivity to cytochrome c-induced apoptosis mediated by PHAPI in breast cancer cells. Cancer Res 66: 2210-8.
67. Beresford PJ, Zhang D, Oh DY, Fan Z, et al. 2001. Granzyme A activates an endoplasmic reticulum-associated caspase-independent nuclease to induce single-stranded DNA nicks. J Biol Chem 276: 43285-93.
68. Mazroui R, Di Marco S, Clair E, von Roretz C, et al. 2008. Caspase-mediated cleavage of HuR in the cytoplasm contributes to pp32/PHAP-I regulation of apoptosis. J Cell Biol 180: 113-27.
69. Chakravarti D, Hong R. 2003. SET-ting the stage for life and death. Cell 112: 589-91.
70. Shen LF, Cheng H, Tsai MC, Kuo HS, et al. 2009. PAL31 may play an important role as inflammatory modulator in the repair process of the spinal cord injury rat. J Neurochem 108: 1187-97.
71. Shen SM, Yu Y, Wu YL, Cheng JK, et al. 2010. Downregulation of ANP32B, a novel substrate of caspase-3, enhances caspase-3 activation and apoptosis induction in myeloid leukemic cells. Carcinogenesis 31: 419-26.
72. Sun W, Kimura H, Hattori N, Tanaka S, et al. 2006. Proliferation related acidic leucine-rich protein PAL31 functions as a caspase-3 inhibitor. Biochem Biophys Res Commun 342: 817-23.
73. Li M, Makkinje A, Damuni Z. 1996. Molecular identification of I1PP2A, a novel potent heat-stable inhibitor protein of protein phosphatase 2A. Biochemistry 35: 6998-7002.
74. Katayose Y, Li M, Al-Murrani SW, Shenolikar S, et al. 2000. Protein phosphatase 2A inhibitors, I(1)(PP2A) and I(2)(PP2A), associate with and modify the substrate specificity of protein phosphatase 1. J Biol Chem 275: 9209-14.
75. Habrukowich C, Han DK, Le A, Rezaul K, et al. 2010. Sphingosine interaction with acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) regulates PP2A activity and cyclooxygenase (COX)-2 expression in human endothelial cells. J Biol Chem 285: 26825-31.
76. Yu LG, Packman LC, Weldon M, Hamlett J, et al. 2004. Protein phosphatase 2A, a negative regulator of the ERK signaling pathway, is activated by tyrosine phosphorylation of putative HLA class II-associated protein I (PHAPI)/pp32 in response to the antiproliferative lectin, jacalin. J Biol Chem 279: 41377-83.
77. Costanzo RV, Vila-Ortiz GJ, Perandones C, Carminatti H, et al. 2006. Anp32e/Cpd1 regulates protein phosphatase 2A activity at synapses during synaptogenesis. Eur J Neurosci 23: 309-24.
78. Sanchez I, Pinol P, Corral-Juan M, Pandolfo M, et al. 2013. A novel function of Ataxin-1 in the modulation of PP2A activity is dysregulated in the spinocerebellar ataxia type 1. Hum Mol Genet 22: 3425-37.
79. Radrizzani M, Vila-Ortiz G, Cafferata EG, Di Tella MC, et al. 2001. Differential expression of CPD1 during postnatal development in the mouse cerebellum. Brain Res 907: 162-74.
80. Bauer A, Neumann S, Karger A, Henning AK, et al. 2014. ANP32B is a nuclear target of henipavirus M proteins. PLoS One 9: e97233.
81. Bodem J, Schied T, Gabriel R, Rammling M, et al. 2011. Foamy virus nuclear RNA export is distinct from that of other retroviruses. J Virol 85: 2333-41.
82. Higashino F, Aoyagi M, Takahashi A, Ishino M, et al. 2005. Adenovirus E4orf6 targets pp32/LANP to control the fate of ARE-containing mRNAs by perturbing the CRM1-dependent mechanism. J Cell Biol 170: 15-20.
83. Itin C, Ulitzur N, Muhlbauer B, Pfeffer SR. 1999. Mapmodulin, cytoplasmic dynein, and microtubules enhance the transport of mannose 6-phosphate receptors from endosomes to the trans-golgi network. Mol Biol Cell 10: 2191-7.
84. Cui CP, Zhang DJ, Shi BX, Du SJ, et al. 2008. Isolation and functional identification of a novel human hepatic growth factor: hepatopoietin Cn. Hepatology 47: 986-95.
85. Cui CP, Wei P, Liu Y, Zhang DJ, et al. 2009. The protective role of Hepatopoietin Cn on liver injury induced by carbon tetrachloride in rats*. Hepatol Res 39: 200-6.
86. Liu Y, Saiyan S, Men TY, Gao HY, et al. 2013. Hepatopoietin Cn reduces ethanol-induced hepatoxicity via sphingosine kinase 1 and sphingosine 1-phosphate receptors. J Pathol 230: 365-76.
87. Zippo A, De Robertis A, Bardelli M, Galvagni F, et al. 2004. Identification of Flk-1 target genes in vasculogenesis: Pim-1 is required for endothelial and mural cell differentiation in vitro. Blood 103: 4536-44.
88. Anisimov SV, Tarasov KV, Tweedie D, Stern MD, et al. 2002. SAGE identification of gene transcripts with profiles unique to pluripotent mouse R1 embryonic stem cells. Genomics 79: 169-76.
89. Brody JR, Kadkol SS, Hauer MC, Rajaii F, et al. 2004. pp32 reduction induces differentiation of TSU-Pr1 cells. Am J Pathol 164: 273-83.
90. Kular RK, Cvetanovic M, Siferd S, Kini AR, et al. 2009. Neuronal differentiation is regulated by leucine-rich acidic nuclear protein (LANP), a member of the inhibitor of histone acetyltransferase complex. J Biol Chem 284: 7783-92.
91. Walensky LD, Coffey DS, Chen TH, Wu TC, et al. 1993. A novel M(r) 32, 000 nuclear phosphoprotein is selectively expressed in cells competent for self-renewal. Cancer Res 53: 4720-6.
92. Yu Y, Shen SM, Zhang FF, Wu ZX, et al. 2012. Acidic leucine-rich nuclear phosphoprotein 32 family member B (ANP32B) contributes to retinoic acid-induced differentiation of leukemic cells. Biochem Biophys Res Commun 423: 721-5.
93. Mutz D, Weise C, Mechai N, Hofmann W, et al. 2006. Integrin alpha3beta1 interacts with I1PP2A/lanp and phosphatase PP1. J Neurosci Res 84: 1759-70.
94. Buszczak M, Paterno S, Lighthouse D, Bachman J, et al. 2007. The carnegie protein trap library: a versatile tool for Drosophila developmental studies. Genetics 175: 1505-31.
95. Mummery-Widmer JL, Yamazaki M, Stoeger T, Novatchkova M, et al. 2009. Genome-wide analysis of Notch signalling in Drosophila by transgenic RNAi. Nature 458: 987-92.
96. Rual JF, Ceron J, Koreth J, Hao T, et al. 2004. Toward improving Caenorhabditis elegans phenome mapping with an ORFeome-based RNAi library. Genome Res 14: 2162-8.
97. Opal P, Garcia JJ, McCall AE, Xu B, et al. 2004. Generation and characterization of LANP/pp32 null mice. Mol Cell Biol 24: 3140-9.
98. Reilly PT, Afzal S, Wakeham A, Haight J, et al. 2010. Generation and characterization of the Anp32e-deficient mouse. PLoS One 5: e13597.
99. Kular RK, Gogliotti RG, Opal P. 2010. Cpd-1 null mice display a subtle neurological phenotype. PLoS One 5: e12649.
100. Wong P, Leo VI, Low M, Mak TW, et al. 2013. Targeted ANP32E mutant mice do not demonstrate obvious movement defects. PLoS One 8: e63815.
101. Reilly PT, Afzal S, Gorrini C, Lui K, et al. 2011. Acidic nuclear phosphoprotein 32kDa (ANP32)B-deficient mouse reveals a hierarchy of ANP32 importance in mammalian development. Proc Natl Acad Sci USA 108: 10243-8.
102. Vazquez-Higuera JL, Mateo I, Sanchez-Juan P, Rodriguez-Rodriguez E, et al. 2011. Genetic variation in the tau protein phosphatase-2A pathway is not associated with Alzheimer's disease risk. BMC Res Notes 4: 327.
103. Harada JN, Shevchenko A, Pallas DC, Berk AJ. 2002. Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to ubiquitination machinery. J Virol 76: 9194-206.
104. Pegoraro G, Marcello A, Myers MP, Giacca M. 2006. Regulation of adeno-associated virus DNA replication by the cellular TAF-I/set complex. J Virol 80: 6855-64.
105. Yan N, Cherepanov P, Daigle JE, Engelman A, et al. 2009. The SET complex acts as a barrier to autointegration of HIV-1. PLoS Pathog 5: e1000327.
106. Adegbola O, Pasternack GR. 2005. Phosphorylated retinoblastoma protein complexes with pp32 and inhibits pp32-mediated apoptosis. J Biol Chem 280: 15497-502.
107. Stelzl U, Worm U, Lalowski M, Haenig C, et al. 2005. A human protein-protein interaction network: a resource for annotating the proteome. Cell 122: 957-68.
108. Bai J, Brody JR, Kadkol SS, Pasternack GR. 2001. Tumor suppression and potentiation by manipulation of pp32 expression. Oncogene 20: 2153-60.
109. Brody JR, Kadkol SS, Mahmoud MA, Rebel JM, et al. 1999. Identification of sequences required for inhibition of oncogene-mediated transformation by pp32. J Biol Chem 274: 20053-5.
110. Chen TH, Brody JR, Romantsev FE, Yu JG, et al. 1996. Structure of pp32, an acidic nuclear protein which inhibits oncogene-induced formation of transformed foci. Mol Biol Cell 7: 2045-56.
111. Shi H, Hood KA, Hayes MT, Stubbs RS. 2011. Proteomic analysis of advanced colorectal cancer by laser capture microdissection and two-dimensional difference gel electrophoresis. J Proteomics 75: 339-51.
112. Ouellet V, Le Page C, Guyot MC, Lussier C, et al. 2006. SET complex in serous epithelial ovarian cancer. Int J Cancer 119: 2119-26.
113. Li C, Ruan HQ, Liu YS, Xu MJ, et al. 2012. Quantitative proteomics reveal up-regulated protein expression of the SET complex associated with hepatocellular carcinoma. J Proteome Res 11: 871-85.
114. Tsukamoto Y, Uchida T, Karnan S, Noguchi T, et al. 2008. Genome-wide analysis of DNA copy number alterations and gene expression in gastric cancer. J Pathol 216: 471-82.
115. Walker BA, Leone PE, Chiecchio L, Dickens NJ, et al. 2010. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 116: e56-65.
116. Bjorck E, Ek S, Landgren O, Jerkeman M, et al. 2005. High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood 105: 2908-15.
117. Volinia S, Mascellani N, Marchesini J, Veronese A, et al. 2008. Genome wide identification of recessive cancer genes by combinatorial mutation analysis. PLoS One 3: e3380.
118. Nowak MA, Boerlijst MC, Cooke J, Smith JM. 1997. Evolution of genetic redundancy. Nature 388: 167-71.